Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza + COVID-19
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Combination vaccines for influenza and COVID-19 are a class of investigational immunotherapies designed to provide simultaneous protection against seasonal influenza viruses and SARS-CoV-2. These products typically combine antigens or genetic sequences (mRNA) from multiple influenza strains—usually quadrivalent, covering H1N1, H3N2, and two B lineages—with components targeting the SARS-CoV-2 spike protein. The primary development programs utilize mRNA technology (e.g., Moderna's mRNA-1083 and Pfizer/BioNTech's PF-07926307) or recombinant protein subunit platforms (e.g., Novavax's CIC vaccine). By integrating these vaccines into a single injection, developers aim to simplify immunization schedules, reduce the burden on healthcare systems, and improve public health compliance during the respiratory virus season.
- Other names
- influenza and COVID-19 combination vaccineCOVID-19-influenza combination vaccineCOVID19-influenza combination vaccineCOVID 19-influenza combination vaccineCIC vaccine
02
Targets
HA (Hemagglutinin)HA0 (Influenza B virus hemagglutinin)SARS-CoV-2 spike
Beyond the preview
Go deeper on influenza + COVID-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza + COVID-19.